BioXcel Therapeutics's three largest insider shareholders as of September 09, 2026 are Vimal Mehta (Ceo And President, 113.84Mn shares), Vincent O'Neill (Chief Medical Officer, 295.61K shares), Vimal Mehta (Ceo And President, 69.82K shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Vincent O'Neill | Chief Medical Officer | 295,613 | 0 | 295,613 | 63.6% | 17 Dec, 2024 |
| 2 | Vimal Mehta | Ceo And President | 69,817 | 0 | 69,817 | 15.0% | 17 Jun, 2026 |
| 3 | Javier Rodriguez | Officer | 26,838 | 0 | 26,838 | 5.8% | 17 Jun, 2026 |
| 4 | Richard I Steinhart | Chief Financial Officer | 26,335 | 0 | 26,335 | 5.7% | 17 Jun, 2026 |
| 5 | Frank Yocca | Chief Scientific Officer | 26,210 | 0 | 26,210 | 5.6% | 17 Jun, 2026 |
| 6 | David J. Mack | Director | 20,317 | 0 | 20,317 | 4.4% | 03 Nov, 2025 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 12 Aug, 2026 | Susan E. Atkins | Director | Acquired A | 17,000 | $0.00 | $0 | 17,000 | Direct |
| 15 Jun, 2026 | Javier Rodriguez | Officer | Acquired M | 35 | — | — | 26,838 | Direct |
| 15 Jun, 2026 | Frank Yocca | Chief Scientific Officer | Acquired M | 35 | — | — | 26,210 | Direct |
| 15 Jun, 2026 | Richard I Steinhart | Chief Financial Officer | Acquired M | 35 | — | — | 26,335 | Direct |
| 15 Jun, 2026 | Vimal Mehta | Ceo And President | Acquired M | 219 | — | — | 69,817 | Direct |
| 15 Jun, 2026 | Frank Yocca | Chief Scientific Officer | Disposed M | 35 | $0.00 | $0 | 212 | Direct |
| 15 Jun, 2026 | Richard I Steinhart | Chief Financial Officer | Disposed M | 35 | $0.00 | $0 | 212 | Direct |
| 15 Jun, 2026 | Javier Rodriguez | Officer | Disposed M | 35 | $0.00 | $0 | 212 | Direct |
| 15 Jun, 2026 | Vimal Mehta | Ceo And President | Disposed M | 219 | $0.00 | $0 | 1,313 | Direct |
| 04 May, 2026 | Frank Yocca | Chief Scientific Officer | Acquired M | 17,500 | — | — | 33,020 | Direct |
| 04 May, 2026 | Javier Rodriguez | Officer | Acquired M | 17,500 | — | — | 33,363 | Direct |
| 04 May, 2026 | Vimal Mehta | Ceo And President | Acquired M | 49,758 | — | — | 89,017 | Direct |
| 20 May, 2026 | Vimal Mehta | Ceo And President | Disposed S | 19,419 | $1.09 | $21.11K | 69,598 | Direct |
| 20 May, 2026 | Frank Yocca | Chief Scientific Officer | Disposed S | 6,845 | $1.09 | $7.43K | 26,175 | Direct |
| 20 May, 2026 | Javier Rodriguez | Officer | Disposed S | 6,560 | $1.08 | $7.11K | 26,803 | Direct |
| 04 May, 2026 | Frank Yocca | Chief Scientific Officer | Disposed M | 17,500 | $0.00 | $0 | 52,500 | Direct |
| 04 May, 2026 | Javier Rodriguez | Officer | Disposed M | 17,500 | $0.00 | $0 | 52,500 | Direct |
| 04 May, 2026 | Vimal Mehta | Ceo And President | Disposed M | 49,758 | $0.00 | $0 | 149,274 | Direct |
| 01 May, 2026 | Javier Rodriguez | Officer | Acquired M | 9,000 | — | — | 15,863 | Direct |
| 01 May, 2026 | Frank Yocca | Chief Scientific Officer | Acquired M | 9,000 | — | — | 15,520 | Direct |